Entero Healthcare Solutions distributes pharmaceuticals and medical devices to retail pharmacies and hospitals across India, operating 138 warehouses covering 475 districts. The core pharma distribution business is a high-volume, low-margin fulfillment model, while the emerging MedTech segment adds higher margins through a demand-generation role. In Q1 FY27, revenue reached Rs. 1,940 crore, up 38.2% year-on-year, with gross margin expanding 147 basis points to 11.4% and EBITDA margin at 5%, up 143 basis points. The Indian pharma distribution market is fragmented, with only a few national players; Entero serves 72,000+ retail customers and 2,300+ hospitals, and its scale allows EBITDA to grow 94% year-on-year, about 2.5 times the revenue growth rate in Q1.
The persistence of these economics comes from a two-way network effect. Entero sources from over 3,000 manufacturers and supplies over 83,400 SKUs, creating high switching costs for both sides. For manufacturers, the company offers all-India reach, high fill rates, and app-based ordering; for customers, a wide product range and daily deliveries. This scale is difficult to replicate, requiring years of infrastructure and trust. In MedTech, distribution is even more concentrated, with few pan-India players, and Entero's commercial role of demand creation and marketing earns gross margins at least double that of pure pharma distribution. The company avoids pure generic-generic, protecting itself from margin erosion.
The inflection is the integration of seven acquisitions closed in FY26, three in MedTech, adding annualized revenue of over Rs. 1,000 crore. Management has guided FY27 consolidated revenue growth of 23% excluding new acquisitions, with a 5% EBITDA margin and 50% EBITDA-to-operating-cash-flow conversion. Q1 FY27 already achieved the 5% margin, and MedTech revenue is on track to cross Rs. 1,000 crore organically during FY27. Eighteen to twenty-four months out, by calendar mid-2028, MedTech should contribute about 20% of revenue, up from over 15% currently, and total revenue could approach Rs. 8,000 crore from the FY26 annualized base of ~Rs. 7,600 crore. EBITDA margin is internally targeted to exceed 6%, driven by mix shift and operating leverage, and ROCE is expected to reach 25-30%, up from 21.1% in Q1 FY27. Working capital days have already improved to 61 from 66 a year ago, with a target of 60.
Management has a track record of setting and largely delivering numeric targets. In FY26, they guided 30% like-for-like revenue growth and 4%+ EBITDA margin; they delivered a 4.0% EBITDA margin (up 67 basis points) and operating cash flow of Rs. 96.2 crore, slightly below the Rs. 100 crore target but within a reasonable band. For FY27, they reaffirmed the 23% growth and 5% margin guidance, and Q1 results already met the margin. They have committed to no major acquisitions in FY27, focusing on integration and organic growth, with minority buyouts on a 2-5 year timeline. IPO funds are largely deployed, interest costs are expected to stabilize, and no equity dilution is planned. The consistency across the four calls is notable; the same numeric targets have been repeated without downgrades.
The earnings path for the next 18-24 months is visible. If FY27 achieves 23% revenue growth and 5% EBITDA margin, then with continued organic growth of around 20% and margin expansion toward 5.5-6%, FY28 EBITDA could grow roughly 30-40%. The key falsifier is the sustainability of the industry growth rate; Q1 FY27 IPM growth was 13.8%, but Entero's organic forecast assumes a lower industry rate, so any slowdown would pressure the 23% guidance. The other watchpoint is working capital: management aims for 60 days but has not revised guidance despite Q1 improvement, and the 50% conversion target is a hard commitment. If EBITDA margin fails to hold above 5% in the next two quarters, the internal target of 6% becomes doubtful. However, given the MedTech mix shift and operating leverage, the trajectory appears coherent.
companyname: Entero Healthcare Solutions Limited ticker: ENTERO sector: Healthcare Distribution / Pharmaceutical & MedTech Distribution Entero Healthcare Solutions is an Indian healthcare products distribution company. It buys pharmaceutical and medical products from 3,300+ manufacturers and resells them to 105,300+ retail pharmacies and 3,600+ hospitals across 523 districts, through a network of 136 warehouses (FY26 annual report). The company was founded in 2018 and in FY26 generated consolid...
Read the full report →margin expansion, new product segment
FY27 revenue growth guided at 23% year-on-year with 5% EBITDA margins, driven by calendarization of acquisitions and organic growth
Guidance downgradedconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Entero Healthcare Solutions Limited and 4,900+ companies.
5-day free pass. No card required.